Skip to main content


COVID-19 Systemic Involvement

The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority.  Lab findings may include a leukocytosis, lymph

Rituximab in Rheumatoid Vasculitis

The Journal of Rheumatology reports a retrospective, single center, analysis of 17 rheumatoid vasculitis patients who responded well to intravenous rituximab (RTX) therapy.

ACR COVID-19 Guidance for Rheumatic Disease Patients

On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.

Post 9/11 Autoimmune Disease Risk

The 9/11/01 terrorist attach on the World Trade Center (WTC)  resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage.  Arthritis & Rheumatology reports that dust cloud exposure among responders and PTSD among

Guselkumab a Hit in Phase III for PsA

The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.

Low Risk with Immunosuppression at Surgery

The Annals of Rheumatic Disease reports that rheumatoid arthritis patients on biologic therapies do not have a greater risk of postoperative infection after hip fracture, abdominopelvic or cardiac surgery compared (compared with those on methotrexate alone) and that glucocorticoids were associated with a dose-dependent increase risk for postoperative infections.

RheumNow Podcast – The Beginning of Something Else (4.10.20)

Dr Jack Cush reviews the news and journal reports from the past week on

Coagulopathy and Antiphospholipid Antibodies with Covid-19

The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies. 

TNR - Grand Rounds: Safety of Biologics & New Agents

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

Incubation Period for COVID-19

The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.

Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.

COVID-19 Susceptibility: Why Do Some Become So Ill?

The differential susceptibility to COVID-19 infection is attributable to socioeconomic factors and genetic differences, that together with environmental factors, human-virus interactions, gender, perhaps blood type, and age-related senescence determine the immune response and the likelihood of developing disease.